Immuneering (NASDAQ:IMRX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at Needham & Company LLC in a report issued on Thursday,Benzinga reports. They presently have a $15.00 target price on the stock.
Separately, Chardan Capital cut their target price on shares of Immuneering from $16.00 to $12.00 and set a "buy" rating for the company in a research note on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $12.60.
Get Our Latest Stock Analysis on Immuneering
Immuneering Stock Performance
Immuneering stock traded up $0.23 during midday trading on Thursday, reaching $1.94. The stock had a trading volume of 1,480,677 shares, compared to its average volume of 2,268,749. The firm's fifty day simple moving average is $2.14 and its 200-day simple moving average is $1.60. Immuneering has a 1-year low of $1.00 and a 1-year high of $8.89. The stock has a market capitalization of $57.52 million, a P/E ratio of -1.04 and a beta of -0.40.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in IMRX. XTX Topco Ltd grew its stake in shares of Immuneering by 37.3% during the second quarter. XTX Topco Ltd now owns 34,159 shares of the company's stock worth $44,000 after buying an additional 9,274 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in shares of Immuneering during the third quarter worth $25,000. Corsair Capital Management L.P. bought a new stake in shares of Immuneering during the third quarter worth $25,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Immuneering during the second quarter worth $44,000. Finally, Tidemark LLC bought a new stake in shares of Immuneering during the third quarter worth $129,000. 67.65% of the stock is owned by institutional investors.
Immuneering Company Profile
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
See Also
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
